Houston medtech startup secures additional $3M for lung cancer diagnostic tool

fresh funding

Prana Thoracic Inc., a Houston medical device company developing a tool for early interception of lung cancer, announced an additional $3 million in funding. Photo via Getty Images

A Houston-based medtech startup with an innovative tool that's aiming to transform lung cancer intervention has closed its series A extension round.

Prana Thoracic announced an additional $3 million in funding, a raise that was oversubscribed by 30 percent, reports the company. The company's series A originally closed in March 2023 at $3 million. In August of 2022, the company secured $3 million in grant funding.

"We are grateful for the overwhelming support from our investors in this financing round. Their confidence in our mission and plan is motivating,” Joanna Nathan, CEO and co-founder of Prana Thoracic, says in a news release. “This additional funding will enable us to accelerate our efforts in bringing precision surgical solutions to lung cancer patients worldwide.”

The extension included participation from new investors, including cultivate(MD), GenHenn Capital, and Houston Angel Network, as well as from prior lead investor New World Angels. Existing investors — Johnson & Johnson Development Corp, Texas Medical Center Venture Fund, and the Cancer Prevention & Research Institute of Texas (CPRIT) — also support the company.

"We are excited to support Prana Thoracic in their mission to improve lung cancer treatment. Their innovative approach has the potential to significantly impact patient outcomes," says Dr. R. Sean Churchill, managing director of cultivate(MD), in the release.

The additional funding will support the company as it advances through its clinical and regulatory plans.

“The team has made remarkable progress in developing this novel and minimally invasive technique for lung tissue excision, which has the potential to transform the diagnosis and treatment of early-stage lung cancer," adds Dr. Edward M. Boyle, founder and director at the company. "Beyond lung applications, they are pioneering new methods to use this technology for other soft tissues and are actively exploring integration with ablation and robotic systems, aligning with the future direction of these fields."

In 2022, Nathan joined the Houston Innovators Podcast to discuss her passion for Prana Thoracic's innovation. Listen to the episode below.

From Your Site Articles
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Axiom Space CEO steps down, search begins for replacement

CEO hunting

Houston-based space exploration company Axiom Space is searching for a new CEO.

Co-founder Mike Suffredini stepped down effective August 9 as CEO. He cites unidentified personal reasons for his transition from CEO to company advisor. Suffredini remains a board member of Axiom Space.

Co-founder Kam Ghaffarian, the company’s executive chairman, is serving as interim CEO until Axiom Space taps Suffredini’s permanent successor.

“We are grateful for Mike’s invaluable contributions to human space exploration and the remarkable growth of Axiom Space,” Ghaffarian says in a news release. “He will continue to offer his unique perspective and expertise as we advance our mission.”

Suffredini — who managed NASA’s International Space Station program from 2005 to 2015 — founded Axiom Space in 2016 with Ghaffarian. The company operates missions to the International Space Station, is building the world’s first commercial space station, and is developing commercial infrastructure for the space economy.

At one point, Suffredini also held the title of president. Axiom Space executive Matt Ondler was promoted to that job in 2023.

Suffredini led the company as it reached numerous milestones, such as:

Earlier this month, Axiom Space named NASA veteran Peggy Whitson, a former student and professor at Houston’s Rice University, as commander of their next global crew heading to the International Space Station aboard a private mission. Whitson and her three fellow crew members arrived in Houston on August 6 to train with Axiom Space, NASA, and SpaceX for Axiom Mission 4. The mission is tentatively scheduled for October.

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes a Houston entrepreneur, a media businessman turned nonprofit leader, and growing geothermal energy company founder.

Megan Eddings, founder of Accel Lifestyle

Megan Eddings shares the full entrepreneurial journey — from founding to a pandemic pivot and an exit — on the Houston Innovators Podcast. Photo courtesy of Megan Eddings

After years of tolling over her athleisure wear startup, Megan Eddings knew what her company needed for it to be successful, and she knew she wasn't the right person to do it.

Accel Lifestyle, a clothing brand based on Edding's patented antimicrobial Prema fabric, launched late in 2019 just ahead of boutique fitness studio craze was significantly affected by the pandemic. After pivoting to face masks, including manufacturing tens of thousands for the United States Military, Eddings says she went into the next few years with Accel being back on track to design stink-resistant workout clothing.

But Eddings knew the company needed a huge marketing push to make a splash in the direct-to-consumer world.

"The core of who I am is not a social media person," she says on the Houston Innovators Podcast. "That isn't my skillset. If you sell a product, one of the only ways to become wildly successful is to have an incredible marketing strategy that you need a lot of money to build and create. That is not something that I liked.

"I was so passionate about inventing something, but in order to really scale to the next level, I would have had to take on quite a bit of investment money," she continues. Read more.

David Gow, president and CEO of the Center for Houston's Future

David Gow has been named president and CEO of the Center for Houston's Future. His role is effective September 3.Photo via CultureMap

A nonprofit organization dedicated to leading Houston into the future has named its next leader.

The Center for Houston’s Future named David Gow as president and CEO, succeeding Brett Perlman, who was announced in April to be remaining at the Center with a focus on the Center’s hydrogen initiative. Gow is the founder and chairman of Gow Media, InnovationMap's parent company. His role is effective September 3.

“I am excited to step into this opportunity with the Center and work with the team, the board and many other stakeholders to help shape Houston’s future,” Gow says in a news release. “The Center presents an exciting opportunity to cast a vision for our region and identify initiatives that will make an impact.”Read more.

Tim Latimer, co-founder and CEO of Fervo Energy

Tim Latimer's Fervo Energy went from a 5,158-square-foot space to a 23,782-square-foot office in downtown Houston. Photo courtesy of Fervo Energy

On the heels of landing more than $240 million in venture capital, Houston-based geothermal power provider Fervo Energy has more than quadrupled the size of its headquarters.

Fervo previously occupied 5,158 square feet at 114 Main St. in downtown Houston. The company recently left the Main Street space and leased 23,782 square feet at downtown Houston’s 910 Louisiana office tower. Houston-based commercial real estate company Hines owns and manages the 50-story former One Shell Plaza.

“We believe Houston is the center of the energy transition, and downtown Houston has long been its center of activity,” Tim Latimer, co-founder and CEO of Fervo Energy, says in a news release. “The availability of dining options, parks, and biking infrastructure continue to be great assets and a huge draw for our team. For these reasons and more, the only place for Fervo’s headquarters is downtown Houston.” Read more.

This new Houston lab is translating genetics research into clinical diagnostics

DNA innovation

A new lab at Baylor College of Medicine is primed to do groundbreaking work in the field of genetics.

Baylor Genetics has paired with Baylor’s department of molecular and human genetics to launch the Medical Genetics Multiomics Laboratory (MGML). The goal for the collaboration is to turn research into clinical diagnostics.

MGML’s freshly launched first clinical test is Whole Transcriptomic RNA Sequencing (WT RNAseq). The new test builds upon the success of existing tests like whole exome sequencing (WES) and whole genome sequencing (WGS) currently on offer from Baylor Genetics by focusing on additional variants that could be missed by the other tests.

Baylor Genetics is offering WT RNAseq to the Undiagnosed Diseases Network (UDN) and its affiliated institutions. For more than a decade, the NIH-funded UDN has united clinical and research experts from across many fields and institutions to give answers to patients with rare genetic diseases. Since it became one of the first institutions to join the UDN in 2014, Baylor Genetics has been the UDN’s sequencing core, using WES, WGS and RNA sequencing to help diagnose patients. The additional offering of WT RNAseq could improve the diagnostic yield by as much as 17 percent.

“This agreement, and the MGML lab, bring to life our vision of innovation, allowing us to co-develop new tests, evaluate in terms of clinical utility, and offer commercially in either a research or clinical setting,” says Dr. Brendan Lee, professor, chair and Robert and Janice McNair Endowed Chair of Molecular and Human Genetics at Baylor College of Medicine, and scientific advisory and board of directors member at Baylor Genetics. “Baylor Genetics is turning around critical high-volume testing, but the challenge is also maintaining our innovative edge and our position as leaders in discovery and genomic health implementation. This agreement is a realization of the vision when Baylor Genetics was founded 10 years ago.”

The lab’s product offerings will continue to expand as it becomes commercially feasible to do so, and the new tests will be used both commercially and clinically.

Baylor Genetics combines the powers of Baylor College of Medicine, which has the NIH’s best-funded department of molecular and human genetics, and Japanese clinical diagnostic testing company H.U. Group Holdings.

View All Listings